News | Astellas Pharma Inc.
WEBFind the latest news and updates from Astellas Pharma Inc., a global biopharmaceutical company. Learn about its products, clinical trials, approvals, financial results and more.
News | Astellas Pharma Inc.
WEBSep 24, 2024 — Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality.
Newsroom | Astellas Pharma Inc.
WEBStories. Mar. 19, 2024 Patient Centricity and AI: Navigating the Promise and Pitfalls. Feb. 28, 2024 Strengthening Cancer Awareness in Malaysia: Creative Campaign Focused on Beauty Salons and Barbershops. Oct. 10, 2023 Astellas’ way of supporting patient organizations focusing on people. SEE ALL STORIES. Spotlights. Integrated Report …
Astellas and Kelonia Therapeutics Enter into Research and License ...
WEBFeb 15, 2024 — Astellas and Kelonia Therapeutics, a biotech company with in vivo gene delivery technology, have entered into a research and license agreement to develop novel CAR-T Cell therapies. The...
Results from Astellas' Phase 3 SPOTLIGHT Trial of Investigational ...
WEBApr 14, 2023 — Zolbetuximab is an investigational antibody that targets CLDN18.2, a protein expressed in gastric and GEJ cancers. The SPOTLIGHT trial showed that zolbetuximab plus chemotherapy improved...
Astellas Highlights Continued Delivery of Strong Cancer Portfolio …
WEBNews provided by. Astellas Pharma Inc. May 25, 2023, 17:00 ET. Share this article. Share to X. Share this article. Share to X. Data at meeting illustrate company's progress in …
Astellas Announces FDA Listing of DIGITIVA™ for the ... - BioSpace
WEBSep 19, 2024 — About Astellas. Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology …
Astellas News Room
WEBApr 20, 2013 — Astellas Receives Approval from the European Commission for VYLOY™ (zolbetuximab) in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer - Zolbetuximab is currently the first and only therapy approved in the European Union to target claudin 18.2, a biomarker positively expressed …
News | Astellas Pharma Inc.
WEBMar 3, 2024 — News from Astellas. Latest and past news available. TOKYO, March 4, 2024 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced dosing of the first patient in the STARLIGHT™ 2 Phase 3 pivotal study for fezolinetant, an investigational oral, nonhormonal compound being studied for the …
News - Astellas Pharma Inc. - Astellas Gene Therapies
WEBAstellas Pharma Inc. announced that it has acquired Audentes Therapeutics, Inc., a company focused on developing AAV-based genetic medicines for rare neuromuscular diseases. The combined company aims to become a global leader in genetic medicines and to expand its pipeline and commercialization efforts.